Chemoprevention of colorectal cancer: systematic review and economic evaluation

Abstract

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

Retracted: Promoter Methylation of theRASSF1AGene may Contribute to Colorectal Cancer Susceptibility: A Meta-Analysis of Cohort Studies

“…Risk factors including diet, obesity, smoking, and alcohol intake have been linked with an increased risk of CRC (Huxley et al, 2009). Moreover, it has been illustrated that about 25% of CRCs are attributable to a family history of CRC, suggesting that genetic and epigenetic factors may also play a crucial role in susceptibility to CRC (Cooper et al, 2010).…”

Familial adenomatous polyposis in China

“…Surgical intervention and chemotherapy has been proven to benefit patients with FAP (64,65,72,73). In China, laparoscopic IPAA surgery is considered the standard treatment for patients diagnosed with CFAP and advanced AFAP (66,67).…”

“…There is a significant number of patients diagnosed with FAP but with no identified genetic mutation, even following sophisticated genetic testing (41,42,44); due to this many high-risk individuals may be misdiagnosed. There is clinical evidence to support the possibility of influencing the manifestation of FAP through chemoprevention and lifestyle changes (72,73). There are certain clinical cases showing the efficacy of TCM in the treatment of FAP, however the active ingredient remains to be elucidated.…”

“…In order to delay the development of adenomas into adenocarcinoma and to prevent the recurrence of adenomas in the retained rectum of patients with FAP following surgical intervention, multiple drugs and dietary supplements have been identified as potential chemopreventatives (72,73). The nonsteroidal anti-inflammatory drug (NSAID) sulindac (74,75) and selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (76,77) are the typical drugs administered to control and reduce polyposis in the retained rectum following surgery.…”

Non-Steroidal Anti-Inflammatory Drugs, DNA Repair and Cancer

“…Protective dietary factors include NSAIDs, fruit, vegetables, and folic acid and possibly calcium, whilst red and processed meat ingestion, alcohol use and obesity are perceived to increase risk (Forte et al, 2008;Key, 2011;La Vecchia et al, 2001;Ryan-Harshman & Aldoori, 2007;Scheier, 2001;Serrano et al, 2004). An assessment of chemopreventative measures, such as NSAID and micronutrient intake, for the general population and individuals with an increased risk for colorectal cancer based on family history, has recently been published (Cooper et al, 2010).…”